MyFinsight
Home
Blog
About
Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$8,683K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net loss
Proceeds from issuance of term d...
Non-cash interest expense
Others
Negative Cash Flow Breakdown
Change in fair value of the conv...
Prepaid expenses and other asset...
Accrued compensation
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
74,141
-115,346
-124,298
-26,675
Depreciation expense
591
457
418
1,113
Stock-based compensation expense
3,391
1,075
632
622
Change in fair value of the convertible loan
-91,018
101,062
105,772
14,643
Non-cash interest expense
6,628
5,555
4,829
4,341
Impairment expense
-
-
5,412
-
Change in right-of-use asset
-511
-516
-594
-587
Prepaid expenses and other assets
2,013
-948
-194
-1,018
Accounts payable and accrued liabilities
206
-352
-310
794
Accrued compensation
-772
624
348
259
Operating lease liability
-331
-321
-265
-257
Net cash used in operating activities
-8,666
-5,782
-6,674
-4,298
Purchases of property and equipment
17
63
52
242
Net cash used in investing activities
-17
-63
-52
-242
Proceeds from issuance of term debt, net of issuance costs
25,000
-
0
15,000
Proceeds from issuance of common stock under atm, net
2,373
-
-
-
Payments for taxes related to net share settlement of equity awards
0
63
0
32
Proceeds from exercise of stock options
508
704
658
-
Net cash provided by financing activities
27,881
641
658
14,968
Net change in cash, cash equivalents and restricted cash
19,198
-5,204
-6,068
10,428
Cash, cash equivalents and restricted cash, beginning of period
8,874
14,078
20,146
14,771
Cash, cash equivalents and restricted cash, end of period
28,072
-
-
-
Debt and warrant amendments recorded as debt discount
20,640
-
-
-
Cash and cash equivalents
23,952
-
-
-
Restricted cash
4,120
-
-
-
Cash, cash equivalents and restricted cash
28,072
8,874
14,078
20,146
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
term debt, net of...
$25,000K
(150.00%↑ Y/Y)
Proceeds from issuance of
common stock under atm,...
$2,373K
Proceeds from exercise of
stock options
$508K
Net cash provided by
financing activities
$27,881K
(179.20%↑ Y/Y)
Net change in cash,
cash equivalents and...
$19,198K
(479.93%↑ Y/Y)
Canceled cashflow
$8,683K
Net loss
$74,141K
(424.81%↑ Y/Y)
Non-cash interest
expense
$6,628K
(-10.41%↓ Y/Y)
Stock-based compensation
expense
$3,391K
(150.07%↑ Y/Y)
Depreciation expense
$591K
Change in right-of-use
asset
-$511K
(56.80%↑ Y/Y)
Accounts payable and
accrued liabilities
$206K
(125.18%↑ Y/Y)
Net cash used in
operating activities
-$8,666K
(41.41%↑ Y/Y)
Net cash used in
investing activities
-$17K
(93.15%↑ Y/Y)
Canceled cashflow
$85,468K
Change in fair value of
the convertible...
-$91,018K
(-16709.12%↓ Y/Y)
Purchases of property and
equipment
$17K
(-93.15%↓ Y/Y)
Prepaid expenses and
other assets
$2,013K
(71.61%↑ Y/Y)
Accrued compensation
-$772K
(-10.92%↓ Y/Y)
Operating lease liability
-$331K
(34.58%↑ Y/Y)
Buy us a coffee